Targeting chronic central nervous system HIV infection

Antiviral Therapy

Volumn 17, Issue 7, 2012, Pages 1227-1231

  Price, Richard W ^a   Swanstrom, Ronald ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR PLUS RITONAVIR; LAMIVUDINE; NEVIRAPINE; RITONAVIR PLUS SAQUINAVIR; TENOFOVIR DISOPROXIL; VIRUS RNA; ZIDOVUDINE;

CD4 LYMPHOCYTE COUNT; CELL CULTURE; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID; DRUG EFFICACY; DRUG PENETRATION; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOCYTE; MONOCYTE EFFICACY SCORE; NEUROPSYCHOLOGICAL TEST; NOTE; PRIORITY JOURNAL; SCORING SYSTEM; VIRUS ENCEPHALITIS; VIRUS LOAD;

COGNITION DISORDERS; FEMALE; HIV-1; HUMANS; MACROPHAGES; MALE; MONOCYTES;

EID: 84870477604     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2414     Document Type: Note

References (37)

1. Ellis RJ, Hsia K, Spector SA, et al. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. Ann Neurol 1997; 42:679-688. (Pubitemid 27481539)
2. Spudich S, Lollo N, Liegler T, Deeks SG, Price RW. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis 2006; 194:1686-1696. (Pubitemid 44901999)
3. Spudich S, Gisslen M, Hagberg L, et al. Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J Infect Dis 2011; 204:753-760.
4. Crews L, Patrick C, Achim CL, Everall IP, Masliah E. Molecular pathology of neuro-AIDS (CNS-HIV). Int J Mol Sci 2009; 10:1045-1063.
5. Navia BA, Cho ES, Petito CK, Price RW. The AIDS dementia complex: II. Neuropathology. Ann Neurol 1986; 19:525-535. (Pubitemid 16085186)
6. Bhaskaran K, Mussini C, Antinori A, et al. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol 2008; 63:213-221. (Pubitemid 351355300)
7. Lescure FX, Omland LH, Engsig FN, et al. Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study. Clin Infect Dis 2011; 15:235-243.
8. Heaton RK, Clifford DB, Franklin DR, Jr., et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75:2087-2096.
9. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011; 62:141-155.
10. Yilmaz A, Price RW, Gisslen M. Antiretroviral drug treatment of CNS HIV-1 infection. J Antimicrob Chemother 2012; 67:299-311.
11. Canestri A, Lescure FX, Jaureguiberry S, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 2010; 50:773-778.
12. Edén A, Fuchs D, Hagberg L, et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis 2010; 202:1819-1825.
13. Queen SE, Mears BM, Kelly KM, et al. Replication-competent simian immunodeficiency virus (SIV) Gag escape mutations archived in latent reservoirs during antiretroviral treatment of SIV-infected macaques. J Virol 2011; 85:9167-9175.
14. Lafeuillade A. Eliminating the HIV reservoir. Curr HIV/ AIDS Rep 2012; 9:121-131.
15. Robertson KR, Su Z, Margolis DM, et al. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology 2010; 74:1260-1266.
16. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65:65-70.
17. Smurzynski M, Wu K, Letendre S, et al. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 2011; 25:357-365.
18. Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009; 23:1359-1366.
19. Ellis RJ, Badiee J, Vaida F, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 2011; 25:1747-1751.
20. Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011; 17:3-16.
21. Cysique LA, Waters EK, Brew BJ. Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research. BMC Neurol 2011; 11:148.
22. Schnell G, Price RW, Swanstrom R, Spudich S. Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection. J Virol 2010; 84:2395-2407.
23. Lyons J, Venna N, Cho TA. Atypical nervous system manifestations of HIV. Semin Neurol 2011; 31:254-265.
24. Gisslén M, Price RW, Nilsson S. The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence? BMC Infect Dis 2011; 11:356.
25. Shikuma CM, Nakamoto B, Shiramizu B, et al. Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV. Antivir Ther 2012; doi: 10.3851/IMP2411.
26. Gavegnano C, Schinazi RF. Antiretroviral therapy in macrophages: implication for HIV eradication. Antivir Chem Chemother 2009; 20:63-78.
27. Valcour VG, Shiramizu BT, Sithinamsuwan P, et al. HIV DNA and cognition in a Thai longitudinal HAART initiation cohort: the SEARCH 001 Cohort Study. Neurology 2009; 72:992-998.
28. Lee B, Sharron M, Montaner LJ, Weissman D, Doms RW. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci U S A 1999; 96:5215-5220. (Pubitemid 29214563)
29. Sonza S, Maerz A, Uren S, et al. Susceptibility of human monocytes to HIV type 1 infection in vitro is not dependent on their level of CD4 expression. AIDS Res Hum Retroviruses 1995; 11:769-776.
30. Naif HM, Li S, Alali M, et al. CCR5 expression correlates with susceptibility of maturing monocytes to human immunodeficiency virus type 1 infection. J Virol 1998; 72:830-836. (Pubitemid 28048908)
31. Arrildt KT, Joseph SB, Swanstrom R. The HIV-1 env protein: a coat of many colors. Curr HIV/AIDS Rep 2012; 9:52-63.
32. Josefsson L, King MS, Makitalo B, et al. Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule. Proc Natl Acad Sci U S A 2011; 108:11199-11204.
33. Spivak AM, Salgado M, Rabi SA, O'Connell KA, Blankson JN. Circulating monocytes are not a major reservoir of HIV-1 in elite suppressors. J Virol 2011; 85:10399-10403.
34. Schnell G, Joseph S, Spudich S, Price RW, Swanstrom R. HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathog 2011; 7:e1002286.
35. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Updated 27 March 2012. Accessed 16 April 2012.) Available from http://aidsinfo.nih.gov/guidelines/html/1/adult-and- adolescent-treatment-guidelines/0/
36. Garvey L, Winston A, Walsh J, et al. Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease. Neurology 2011; 76:693-700.
37. Mankowski JL, Queen SE, Clements JE, Zink MC. Cerebrospinal fluid markers that predict SIV CNS disease. J Neuroimmunol 2004; 157:66-70. (Pubitemid 39576639)